Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

January 15, 2024

Study Completion Date

January 19, 2024

Conditions
Neovascular Age-related Macular Degeneration
Interventions
DRUG

Faricimab

The Injections were performed according to local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of eye speculum, topical 5% povidone-iodine disinfection, a 30G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in supertemporal or inferotemporal quadrants, a sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.

Trial Locations (1)

2600

Miklos Schneider, Glostrup Municipality

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT06231121 - Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab | Biotech Hunter | Biotech Hunter